[Form 4] RenovoRx, Inc. Insider Trading Activity

Rhea-AI Filing Summary

RenovoRx, Inc. director Laurence J. Marton reported a non‑derivative transaction and a derivative grant on 10/01/2025. He was granted 47,640 stock option awards with an exercise price of $1.34, exercisable beginning 10/01/2025 and expiring 10/01/2035. The option shares vest in 12 equal monthly installments starting 11/01/2025. The Form 4 was signed and filed on 10/03/2025. The report lists Mr. Marton as a director and the filing indicates the options are held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Marton Laurence

(Last) (First) (Middle)

C/O RENOVORX, INC.

2570 W EL CAMINO REAL, SUITE 320

(Street)

MOUNTAIN VIEW CA 94040

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RenovoRx, Inc. [ RNXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.34	10/01/2025		A		47,640		(1)	10/01/2035	Common Stock	47,640	$0	47,640	D

Explanation of Responses:

1. The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2025.

	/s/ Laurence J. Marton	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did RenovoRx (RNXT) disclose in the Form 4 filed by Laurence J. Marton?

The Form 4 reports a grant of 47,640 stock options to director Laurence J. Marton with an exercise price of $1.34 and a 10/01/2035 expiration.

When do Mr. Marton's options vest and become exercisable?

The options are exercisable on 10/01/2025 and vest in 12 equal monthly installments beginning on 11/01/2025.

How many shares does Mr. Marton beneficially own after the reported transaction?

Following the reported transaction, Mr. Marton beneficially owns 47,640 shares underlying the option award.

What is the filing date for the Form 4 reporting this transaction?

The Form 4 was signed and filed on 10/03/2025 and reports a transaction dated 10/01/2025.

What is Laurence Marton's role at RenovoRx as stated on the Form 4?

The Form 4 identifies Laurence J. Marton as a director of RenovoRx, Inc.